HMS Capital Management LLC Buys New Shares in United Therapeutics Co. (NASDAQ:UTHR)

HMS Capital Management LLC purchased a new stake in United Therapeutics Co. (NASDAQ:UTHR) during the 3rd quarter, Holdings Channel.com reports. The fund purchased 1,331 shares of the biotechnology company’s stock, valued at approximately $477,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Meiji Yasuda Asset Management Co Ltd. increased its holdings in United Therapeutics by 1.6% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company’s stock valued at $652,000 after buying an additional 33 shares during the period. Toronto Dominion Bank grew its holdings in shares of United Therapeutics by 0.8% in the 2nd quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company’s stock worth $1,441,000 after purchasing an additional 37 shares during the last quarter. ClariVest Asset Management LLC grew its holdings in shares of United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 42 shares during the last quarter. Benjamin F. Edwards & Company Inc. grew its holdings in shares of United Therapeutics by 14.0% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 42 shares during the last quarter. Finally, First Citizens Bank & Trust Co. grew its holdings in shares of United Therapeutics by 1.8% in the 3rd quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company’s stock worth $961,000 after purchasing an additional 48 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

UTHR has been the topic of several analyst reports. TD Cowen upped their target price on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Argus increased their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Morgan Stanley lowered shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price objective for the stock from $310.00 to $321.00 in a report on Thursday, July 11th. Jefferies Financial Group increased their price objective on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. Finally, Wells Fargo & Company increased their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a report on Tuesday, August 20th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $370.86.

Insider Transactions at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $328.39, for a total transaction of $1,182,204.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $42,690.70. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CEO Martine A. Rothblatt sold 269 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $348.41, for a total value of $93,722.29. Following the completion of the sale, the chief executive officer now directly owns 130 shares in the company, valued at $45,293.30. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $328.39, for a total value of $1,182,204.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $42,690.70. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 85,022 shares of company stock worth $30,412,032. 11.90% of the stock is owned by company insiders.

United Therapeutics Stock Up 1.6 %

NASDAQ:UTHR opened at $382.77 on Wednesday. The firm has a market capitalization of $17.09 billion, a price-to-earnings ratio of 16.81, a price-to-earnings-growth ratio of 1.08 and a beta of 0.56. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $382.95. The stock’s 50 day moving average price is $356.00 and its two-hundred day moving average price is $318.81.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping the consensus estimate of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business’s quarterly revenue was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.38 EPS. As a group, analysts anticipate that United Therapeutics Co. will post 25.57 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.